STAR-LLD seeks to replace standard care for blood cancers
Starton Therapeutics announced it has dosed the first patient in its Phase IIa study evaluating STAR-LLD for the treatment of relapsed/refractory multiple myeloma (RRMM).
STAR-LLD is a continuous delivery lenalidomide (LLD) in development seeking to expand and replace the standard-of-care for the most common blood cancers, multiple myeloma (MM), and chronic lymphocytic leukaemia (CLL).
“STAR-LLD is designed to improve tolerability while maintaining meaningful minimum effective dose delivery of lenalidomide, which we believe will mitigate the toxic effects of the therapy compared to oral lenalidomide,” said Jamie Oliver, Chief Medical Officer at Starton Therapeutics. “Building on encouraging early clinical experience through our Phase Ib trial, we look forward to advancing STAR-LLD in the next stage of development and to further establish its potential in enabling more patients to remain on therapy longer to experience the full potential benefit of treatment”.
Positive responses in Phase I trial
The Phase II study is expanding from two to six investigational sites across the United States, broadening its geographic reach and patient access.
The study’s original sites are led by Dr Nash Gabrail in Canton, Ohio, and Dr Keith Lerro in Wilson, North Carolina. Dr Gabrail noted: “We are excited to expand the use of STAR-LLD in relapsed and refractory multiple myeloma. Our experience with the Phase Ib study demonstrated positive responses and no meaningful haematologic toxicity, which had a notable impact on the patients’ experience.”
The Phase Ib clinical study of six relapsed/refractory MM patients resulted in all patients that received STAR-LLD achieving an objective response (one complete response and five partial responses).
The Phase II study will compare three doses of continuous subcutaneous infusion with STAR-LLD, combined with dexamethasone and a proteasome inhibitor (PI), to oral lenalidomide (Revlimid) with the same combination. It will enrol 24 transplant ineligible patients in 2nd or greater line of therapy and has the option to expand enrolment to a total of 69 patients based on tolerability of selected dose (TSD) and response rate.
A preclinical proof-of-concept study for subcutaneous STAR-LLD demonstrated that MM tumours caused by human myeloma cells grew 25-fold if untreated, five-fold when treated with daily lenalidomide, and shrank by 80% with STAR-LLD over a single 28-day cycle.
The study also showed a 100% overall response rate (ORR) using continuous delivery LLD with 20% of animals in this cohort tumour-free after 100 days; by contrast, there was a 0% ORR in animals treated with a 70% higher dose of lenalidomide given in single daily doses.
